Retatrutide FDA Approval: Timeline, Status, and What Comes Next

The most powerful weight loss drug ever tested in clinical trials had its first major breakthrough in December 2025: Eli Lilly's retatrutide passed its first Phase 3 trial, delivering an average of 71.2 pounds of weight loss. The question everyone is now asking is: when can patients actually get it?

The honest answer involves understanding how the FDA drug approval process works — and it takes time.

Current Status (Early 2026)

Retatrutide is currently in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. Here's where things stand:

• Phase 1: Completed
• Phase 2: Completed — showed 24.2% average weight loss (NEJM, 2023)
• Phase 3 (TRIUMPH-1): Positive topline results announced December 2025 — 71.2 lbs average weight loss, all primary endpoints met
• Phase 3 (remaining trials): 7 additional readouts expected in 2026
• NDA submission: Not yet filed
• FDA approval: Not yet granted

Phase 3 Trial Results (December 2025)

On December 11, 2025, Eli Lilly announced that retatrutide met all primary and key secondary endpoints in its first Phase 3 obesity trial (TRIUMPH-1). Key findings:

• Average weight loss: 71.2 lbs — approximately 30% of body weight
• All primary endpoints met
• All key secondary endpoints met
• Additional finding: significant reduction in osteoarthritis pain — an unexpected secondary benefit that could expand the drug's approved indications

The osteoarthritis result is notable. It suggests retatrutide may have direct anti-inflammatory effects beyond what can be attributed to weight loss alone — possibly through the glucagon receptor pathway affecting joint inflammation. If confirmed in additional trials, this could support a broader FDA label.

Remaining Phase 3 Trials

Eli Lilly has seven additional Phase 3 TRIUMPH trials expected to report results in 2026. These include:

• Maintenance dosing studies (4mg dose in addition to 9mg and 12mg)
• Type 2 diabetes studies
• Cardiovascular outcomes data (critical for regulatory approval and insurance coverage)
• Kidney disease and other metabolic comorbidity studies
• Special populations (different BMI ranges, age groups)

The FDA will require data from multiple trials — not just TRIUMPH-1 — before approving retatrutide. The full Phase 3 dataset takes time to collect and analyze.

Projected FDA Submission Timeline

Here's the realistic sequence of events:

• 2026 Q1-Q3: Remaining Phase 3 readouts
• 2026 Q3-Q4: Eli Lilly compiles complete NDA package
• Late 2026 or early 2027: NDA submission to FDA
• 2027: FDA review period (typically 6-12 months, or 6 months for priority review)
• Late 2027 (optimistic) or 2028 (conservative): FDA approval decision

Even with Breakthrough Therapy designation, this timeline cannot be significantly shortened. The FDA needs a complete safety and efficacy package — which requires time to collect, analyze, and submit.

The one wildcard: if Eli Lilly pursues a rolling submission (submitting completed trial sections as they're finished, rather than all at once), the review process can begin earlier. They've done this with other drugs. If rolling submission is granted, approval could come sooner than the estimate above.

What Approval Would Mean for Access

When retatrutide is approved, access will depend on several factors:

Insurance coverage: This is the biggest unknown. Medicare currently doesn't cover TRT drugs for obesity (only for diabetes). Commercial insurers vary. If retatrutide is approved for obesity, the same coverage battles that semaglutide and tirzepatide face will apply.

Compounding: Once FDA approved and if supply is limited, compounding pharmacies may be allowed to produce retatrutide under the drug shortage provisions — similar to what happened with semaglutide and tirzepatide. This would dramatically expand affordability.

Telehealth access: Expect every major TRT telehealth provider to add retatrutide immediately upon approval. The infrastructure is already built.

How to Prepare Now

If you're interested in retatrutide and want to be ready when it becomes available:

1. Establish care with a TRT prescriber now. Having an existing relationship with a telehealth provider who prescribes TRT medications means they'll likely offer retatrutide as soon as it's available.
2. Consider tirzepatide in the interim. Tirzepatide delivers ~22% weight loss and is available now. If you have significant weight to lose, starting tirzepatide now may make more sense than waiting 18+ months.
3. Check ClinicalTrials.gov for open TRIUMPH trials. If you qualify, trial participation gets you access to the drug now at no cost.
4. Watch for Lilly announcements. Subscribe to Eli Lilly's investor news or a TRT news source for NDA submission announcements.